BMS/AZ’s Komboglyze A Non-Starter At IQWiG For Diabetes Type 2
This article was originally published in The Pink Sheet Daily
Executive Summary
IQWiG of Germany has rejected Bristol/AstraZeneca’s Komboglyze for diabetes type 2 on procedural grounds, including use of the wrong comparator. The watchdog’s decision should induce manufacturers to negotiate early with health technology assessment bodies.